atovaquone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	258	95233-18-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: 566C80 atovaquone mepron	A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols. Molecular weight: 366.84 Formula: C22H19ClO3 CLOGP: 6.03 LIPINSKI: 1 HAC: 3 HDO: 1 TPSA: 54.37 ALOGS: -5.66 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

566C80
atovaquone
mepron

A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.

Molecular weight: 366.84
Formula: C22H19ClO3
CLOGP: 6.03
LIPINSKI: 1
HAC: 3
HDO: 1
TPSA: 54.37
ALOGS: -5.66
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.25	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	58.41 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	23 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	0.15 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.00 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	63 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	0.00 mg/mL	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company	Orphan
Nov. 25, 1992	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malaria	83.09	17.33	15	6257	205	63482545
Pyrexia	68.39	17.33	146	6126	470332	63012418
Pancytopenia	58.05	17.33	59	6213	96874	63385876
Babesiosis	57.09	17.33	11	6261	218	63482532
Cerebellar stroke	54.34	17.33	11	6261	283	63482467
Rash maculo-papular	50.10	17.33	34	6238	31862	63450888
Encephalopathy	46.47	17.33	35	6237	38585	63444165
Cytokine release syndrome	42.60	17.33	23	6249	14291	63468459
Stevens-Johnson syndrome	42.56	17.33	28	6244	24922	63457828
Agranulocytosis	39.96	17.33	27	6245	25107	63457643
Partial seizures	37.75	17.33	16	6256	5826	63476924
Toxic epidermal necrolysis	37.41	17.33	26	6246	25308	63457442
Neutropenia	35.92	17.33	63	6209	174942	63307808
Hepatocellular injury	35.59	17.33	26	6246	27355	63455395
Thrombocytopenia	34.43	17.33	57	6215	151100	63331650
Cell death	34.39	17.33	12	6260	2589	63480161
Cytomegalovirus viraemia	31.69	17.33	14	6258	5635	63477115
Febrile neutropenia	28.77	17.33	46	6226	118403	63364347
Rash morbilliform	27.96	17.33	11	6261	3314	63479436
Dermatitis acneiform	26.80	17.33	12	6260	4984	63477766
Diarrhoea	26.77	17.33	140	6132	715226	62767524
Eosinophilia	25.99	17.33	20	6252	22736	63460014
Toxic skin eruption	25.79	17.33	16	6256	12869	63469881
Nocardiosis	25.68	17.33	9	6263	1967	63480783
Hepatic cytolysis	25.57	17.33	17	6255	15390	63467360
Cytomegalovirus infection	25.22	17.33	19	6253	20933	63461817
Systemic candida	24.73	17.33	10	6262	3235	63479515
Phyllodes tumour	24.58	17.33	4	6268	28	63482722
Colitis	24.50	17.33	27	6245	48501	63434249
Pain	23.75	17.33	23	6249	740605	62742145
Multiple organ dysfunction syndrome	22.68	17.33	28	6244	56724	63426026
Sepsis	22.64	17.33	48	6224	153075	63329675
Myeloid maturation arrest	21.37	17.33	3	6269	6	63482744
Lobular breast carcinoma in situ	21.17	17.33	4	6268	71	63482679
Haemophagocytic lymphohistiocytosis	20.77	17.33	13	6259	10614	63472136
Bronchopulmonary aspergillosis	20.59	17.33	12	6260	8623	63474127
Plasma cell myeloma	19.92	17.33	21	6251	35884	63446866
Escherichia bacteraemia	19.79	17.33	9	6263	3874	63478876
Joint vibration	19.30	17.33	3	6269	15	63482735
Infection protozoal	19.13	17.33	3	6269	16	63482734
Mucosal discolouration	18.06	17.33	5	6267	503	63482247
Arthralgia	17.88	17.33	18	6254	569692	62913058
Plasmodium falciparum infection	17.87	17.33	3	6269	26	63482724
Platelet count decreased	17.85	17.33	37	6235	116085	63366665
Graft versus host disease	17.73	17.33	10	6262	6753	63475997
Drug resistance	17.56	17.33	16	6256	22917	63459833
Cytopenia	17.34	17.33	12	6260	11589	63471161

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nocardiosis	158.89	16.80	53	8742	3898	34944238
Malacoplakia	114.82	16.80	26	8769	436	34947700
Immune reconstitution inflammatory syndrome	108.43	16.80	50	8745	8709	34939427
Pancytopenia	70.13	16.80	102	8693	95055	34853081
Pneumocystis jirovecii pneumonia	66.03	16.80	48	8747	19662	34928474
Malaria	63.34	16.80	14	8781	209	34947927
Pyrexia	63.06	16.80	205	8590	332808	34615328
Thrombocytopenia	61.68	16.80	127	8668	156120	34792016
Neutropenia	61.38	16.80	127	8668	156651	34791485
Mucormycosis	52.66	16.80	27	8768	5915	34942221
Phalangeal hypoplasia	52.11	16.80	10	8785	70	34948066
Klebsiella infection	51.31	16.80	30	8765	8501	34939635
Enterococcal infection	48.90	16.80	30	8765	9276	34938860
Drug reaction with eosinophilia and systemic symptoms	42.85	16.80	47	8748	32965	34915171
Cytokine release syndrome	39.54	16.80	38	8757	22839	34925297
Scrotal ulcer	38.69	16.80	11	8784	472	34947664
Hepatocellular injury	38.58	16.80	37	8758	22174	34925962
Penile ulceration	37.78	16.80	11	8784	514	34947622
Drug resistance	37.32	16.80	39	8756	25888	34922248
Persecutory delusion	35.94	16.80	16	8779	2564	34945572
Congenital foot malformation	35.11	16.80	10	8785	432	34947704
Toxoplasmosis	35.05	16.80	13	8782	1303	34946833
Babesiosis	34.84	16.80	8	8787	143	34947993
Escherichia infection	34.43	16.80	23	8772	8222	34939914
Parasite blood test positive	34.09	16.80	5	8790	3	34948133
Proteus infection	33.46	16.80	12	8783	1094	34947042
Staphylococcal skin infection	32.02	16.80	11	8784	883	34947253
Plasmodium falciparum infection	31.02	16.80	6	8789	44	34948092
Mycobacterial infection	30.77	16.80	14	8781	2360	34945776
Alpha haemolytic streptococcal infection	28.91	16.80	11	8784	1183	34946953
Cellulitis staphylococcal	28.90	16.80	10	8785	820	34947316
Anal ulcer	28.26	16.80	10	8785	876	34947260
Septic shock	27.79	16.80	58	8737	71776	34876360
Cutaneous mucormycosis	27.74	16.80	7	8788	189	34947947
Myopia	25.84	16.80	10	8785	1126	34947010
Gastrointestinal tract mucosal pigmentation	25.51	16.80	8	8787	482	34947654
Febrile neutropenia	25.49	16.80	84	8711	136765	34811371
Graft versus host disease	25.08	16.80	21	8774	10548	34937588
Thrombotic microangiopathy	24.97	16.80	21	8774	10609	34937527
Pulmonary nocardiosis	24.30	16.80	9	8786	899	34947237
Drug level increased	22.86	16.80	28	8767	22068	34926068
Encephalopathy	21.91	16.80	35	8760	35284	34912852
Chylothorax	21.85	16.80	8	8787	773	34947363
Cutaneous malacoplakia	21.64	16.80	5	8790	92	34948044
Cholestasis	21.43	16.80	30	8765	26918	34921218
Morganella infection	20.97	16.80	7	8788	515	34947621
Cytomegalovirus chorioretinitis	19.95	16.80	12	8783	3577	34944559
Histoplasmosis	19.82	16.80	9	8786	1509	34946627
Immune effector cell-associated neurotoxicity syndrome	19.58	16.80	12	8783	3701	34944435
Acute kidney injury	19.35	16.80	137	8658	304851	34643285
Acute generalised exanthematous pustulosis	19.33	16.80	15	8780	6761	34941375
Bacteraemia	18.82	16.80	24	8771	19693	34928443
Rash maculo-papular	18.76	16.80	29	8766	28422	34919714
Cutaneous extramedullary haemopoiesis	18.57	16.80	3	8792	6	34948130
Infectious pleural effusion	18.41	16.80	10	8785	2460	34945676
Myocardial infarction	18.38	16.80	4	8791	121081	34827055
Acute respiratory distress syndrome	17.87	16.80	27	8768	25942	34922194
Optic neuropathy	17.61	16.80	9	8786	1956	34946180
Acute myeloid leukaemia	17.06	16.80	22	8773	18248	34929888
Disseminated intravascular coagulation	16.92	16.80	24	8771	21792	34926344

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nocardiosis	198.31	15.34	62	13244	5617	79725465
Malacoplakia	117.16	15.34	26	13280	610	79730472
Pancytopenia	116.82	15.34	141	13165	165604	79565478
Pyrexia	107.83	15.34	301	13005	678408	79052674
Immune reconstitution inflammatory syndrome	100.03	15.34	48	13258	13793	79717289
Malaria	98.74	15.34	21	13285	401	79730681
Neutropenia	98.67	15.34	174	13132	287536	79443546
Thrombocytopenia	89.09	15.34	159	13147	265100	79465982
Cytokine release syndrome	81.91	15.34	59	13247	35939	79695143
Babesiosis	78.90	15.34	17	13289	346	79730736
Pneumocystis jirovecii pneumonia	75.61	15.34	54	13252	32454	79698628
Hepatocellular injury	69.38	15.34	60	13246	47533	79683549
Encephalopathy	63.94	15.34	67	13239	67330	79663752
Rash maculo-papular	59.09	15.34	59	13247	56019	79675063
Febrile neutropenia	58.54	15.34	123	13183	230876	79500206
Mucormycosis	54.09	15.34	27	13279	8442	79722640
Drug reaction with eosinophilia and systemic symptoms	50.73	15.34	58	13248	64186	79666896
Klebsiella infection	50.70	15.34	32	13274	15688	79715394
Drug resistance	49.31	15.34	47	13259	42166	79688916
Agranulocytosis	48.59	15.34	48	13258	44982	79686100
Penile ulceration	44.46	15.34	11	13295	418	79730664
Scrotal ulcer	44.43	15.34	11	13295	419	79730663
Thrombotic microangiopathy	43.47	15.34	32	13274	20137	79710945
Septic shock	42.92	15.34	75	13231	122726	79608356
Graft versus host disease	42.10	15.34	28	13278	14998	79716084
Cerebellar stroke	41.57	15.34	11	13295	548	79730534
Persecutory delusion	41.57	15.34	19	13287	4890	79726192
Acute kidney injury	41.55	15.34	184	13122	519220	79211862
Enterococcal infection	41.05	15.34	28	13278	15632	79715450
Pulmonary nocardiosis	40.33	15.34	13	13293	1298	79729784
Sepsis	37.21	15.34	114	13192	269314	79461768
Pain	36.80	15.34	38	13268	703764	79027318
Cytopenia	36.58	15.34	29	13277	20354	79710728
Cytomegalovirus viraemia	36.18	15.34	24	13282	12797	79718285
Parasite blood test positive	36.14	15.34	5	13301	3	79731079
Arthralgia	35.79	15.34	26	13280	571777	79159305
Stevens-Johnson syndrome	35.47	15.34	38	13268	39128	79691954
Plasmodium falciparum infection	35.29	15.34	7	13299	93	79730989
Toxoplasmosis	34.58	15.34	14	13292	2683	79728399
Toxic skin eruption	34.30	15.34	29	13277	22264	79708818
Proteus infection	34.23	15.34	13	13293	2105	79728977
Cell death	33.05	15.34	16	13290	4683	79726399
Cholestasis	32.88	15.34	42	13264	52067	79679015
Escherichia infection	30.98	15.34	25	13281	17992	79713090
Systemic candida	30.38	15.34	17	13289	6689	79724393
Staphylococcal skin infection	30.28	15.34	11	13295	1573	79729509
Completed suicide	30.22	15.34	3	13303	245764	79485318
Cutaneous mucormycosis	30.08	15.34	7	13299	204	79730878
Drug level increased	29.95	15.34	35	13271	39616	79691466
Colitis	29.90	15.34	48	13258	73259	79657823
Immune effector cell-associated neurotoxicity syndrome	29.74	15.34	16	13290	5832	79725250
Aspergillus infection	29.63	15.34	25	13281	19136	79711946
Cellulitis staphylococcal	29.54	15.34	10	13296	1163	79729919
Fall	29.43	15.34	23	13283	487606	79243476
Pancreatitis acute	28.23	15.34	38	13268	49566	79681516
Anal ulcer	27.96	15.34	10	13296	1368	79729714
Eosinophilia	27.75	15.34	36	13270	45309	79685773
Haemophagocytic lymphohistiocytosis	26.81	15.34	25	13281	21812	79709270
Alpha haemolytic streptococcal infection	26.03	15.34	11	13295	2349	79728733
Disseminated intravascular coagulation	26.01	15.34	31	13275	35811	79695271
Acute respiratory distress syndrome	25.44	15.34	34	13272	44033	79687049
Staphylococcal infection	24.92	15.34	39	13267	58256	79672826
Cytomegalovirus infection	24.77	15.34	33	13273	42611	79688471
Myopia	24.55	15.34	10	13296	1946	79729136
Toxic epidermal necrolysis	23.63	15.34	33	13273	44548	79686534
Rash morbilliform	23.62	15.34	14	13292	6136	79724946
Partial seizures	23.40	15.34	16	13290	8962	79722120
Plasma cell myeloma	23.28	15.34	36	13270	53223	79677859
Phalangeal hypoplasia	23.02	15.34	4	13302	24	79731058
Gastrointestinal tract mucosal pigmentation	22.75	15.34	8	13298	1042	79730040
Gamma-glutamyltransferase increased	22.57	15.34	36	13270	54644	79676438
Joint swelling	22.50	15.34	10	13296	288636	79442446
Cutaneous malacoplakia	22.46	15.34	5	13301	119	79730963
Pneumonia fungal	22.40	15.34	17	13289	11193	79719889
Phyllodes tumour	22.36	15.34	4	13302	29	79731053
Platelet count decreased	22.02	15.34	77	13229	194587	79536495
Congenital foot malformation	21.90	15.34	4	13302	33	79731049
Bacteraemia	21.57	15.34	27	13279	32797	79698285
Peripheral swelling	21.55	15.34	9	13297	269608	79461474
Infectious pleural effusion	21.18	15.34	11	13295	3733	79727349
Nasopharyngitis	21.07	15.34	8	13298	253873	79477209
COVID-19 pneumonia	21.01	15.34	25	13281	28824	79702258
Bronchopulmonary aspergillosis	20.83	15.34	22	13284	22272	79708810
Diarrhoea	20.27	15.34	230	13076	880259	78850823
Lobular breast carcinoma in situ	19.91	15.34	4	13302	57	79731025
Pain in extremity	19.78	15.34	19	13287	364519	79366563
Arthropathy	19.72	15.34	3	13303	177108	79553974
Acanthamoeba infection	19.68	15.34	6	13300	499	79730583
Histoplasmosis	19.54	15.34	9	13297	2356	79728726
Syphilis	19.13	15.34	6	13300	548	79730534
Morganella infection	18.51	15.34	7	13299	1120	79729962
Respiratory failure	18.29	15.34	69	13237	180842	79550240
Acute generalised exanthematous pustulosis	17.88	15.34	18	13288	17236	79713846
Joint vibration	17.72	15.34	3	13303	15	79731067
Hepatic function abnormal	17.40	15.34	38	13268	73069	79658013
Transaminases increased	17.28	15.34	31	13275	51712	79679370
Infection protozoal	17.26	15.34	3	13303	18	79731064
Alanine aminotransferase increased	17.26	15.34	63	13243	162507	79568575
Cytomegalovirus chorioretinitis	17.26	15.34	11	13295	5479	79725603
Dermatitis exfoliative generalised	16.76	15.34	12	13294	7229	79723853
Aspartate aminotransferase increased	16.68	15.34	56	13250	138585	79592497
Jaundice	16.60	15.34	31	13275	53318	79677764
Mycobacterium avium complex infection	16.44	15.34	10	13296	4590	79726492
Hepatic necrosis	16.44	15.34	13	13293	9087	79721995
Organising pneumonia	16.35	15.34	14	13292	10925	79720157
Optic neuropathy	16.24	15.34	9	13297	3475	79727607
Hepatotoxicity	16.18	15.34	30	13276	51322	79679760
Off label use	16.16	15.34	226	13080	906989	78824093
Febrile bone marrow aplasia	16.16	15.34	15	13291	13005	79718077
Rash papular	15.98	15.34	19	13287	21897	79709185
Mycobacterial infection	15.81	15.34	9	13297	3659	79727423
Hepatic cytolysis	15.75	15.34	21	13285	27130	79703952
Haemolytic anaemia	15.62	15.34	17	13289	17803	79713279
Rash	15.56	15.34	156	13150	578202	79152880
Escherichia bacteraemia	15.48	15.34	11	13295	6551	79724531
Disease recurrence	15.47	15.34	27	13279	44082	79687000
Musculoskeletal stiffness	15.40	15.34	5	13301	175003	79556079
Dermatitis acneiform	15.37	15.34	13	13293	9980	79721102

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P01AX06	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES Other agents against amoebiasis and other protozoal diseases
ATC	P01BB51	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS ANTIMALARIALS Biguanides
FDA EPC	N0000175482	Antimalarial
FDA EPC	N0000175485	Antiprotozoal
CHEBI has role	CHEBI:35718	antifungal agents
CHEBI has role	CHEBI:38068	antimalarials
CHEBI has role	CHEBI:38503	NADH-coenzyme Q oxidoreductase inhibitors
CHEBI has role	CHEBI:77103	DHODH inhibitor
CHEBI has role	CHEBI:77106	inhibitor of quinol--cytochrome-c reductase (EC 1.10.2.2)
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000962	Antimalarials
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D004791	Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Falciparum malaria	indication	62676009	DOID:14067
Pneumocystosis jiroveci pneumonia	indication	415125002	DOID:11339
Chloroquine-Resistant Plasmodium Falciparum Malaria Prevention	indication
Plasmodium Falciparum Malaria Prevention	indication
Pneumocystis Carinii Pneumonia Prevention	indication
Babesiosis	off-label use	21061004	DOID:9643
Vivax malaria	off-label use	27052006	DOID:12978
Toxoplasmosis	off-label use	187192000	DOID:9965
Toxoplasmosis associated with acquired immunodeficiency syndrome	off-label use	421666009
Toxoplasmosis Prevention	off-label use
Acute nephropathy	contraindication	58574008
Hepatic failure	contraindication	59927004
Hyperglycemia	contraindication	80394007	DOID:4195
Anemia due to enzyme deficiency	contraindication	111577008
Disease of liver	contraindication	235856003	DOID:409
Chronic diarrhea	contraindication	236071009
Vomiting	contraindication	422400008
Malabsorption States	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.18	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
ATP-binding cassette sub-family G member 2	Transporter	Q9UNQ0	ABCG2_HUMAN		IC50	6.64	CHEMBL
Dihydroorotate dehydrogenase (quinone), mitochondrial	Enzyme	Q02127	PYRD_HUMAN		IC50	5.03	WOMBAT-PK
Cytochrome b	Enzyme		CYB_PLAFA	INHIBITOR			CHEMBL	CHEMBL
Ubiquinol-cytochrome-c reductase complex core protein I, mitochondrial	Enzyme		QCR1_EUGGR				WOMBAT-PK
Dihydroorotate dehydrogenase (quinone), mitochondrial	Enzyme		PYRD_RAT		IC50	6.15	CHEMBL
Dihydroorotate dehydrogenase	Enzyme		Q54A96_PLAFA		Ki	4.57	CHEMBL
Dihydroorotate dehydrogenase	Enzyme		G4VFD7_SCHMA		IC50	6.37	CHEMBL

External reference:

ID	Source
4020594	VUID
N0000148284	NUI
D00236	KEGG_DRUG
114972	RXNORM
C0165603	UMLSCUI
CHEBI:575568	CHEBI
AOQ	PDB_CHEM_ID
CHEMBL1450	ChEMBL_ID
DB01117	DRUGBANK_ID
D053626	MESH_DESCRIPTOR_UI
74989	PUBCHEM_CID
9695	IUPHAR_LIGAND_ID
6914	INN_ID
Y883P1Z2LT	UNII
1907	MMSL
213467	MMSL
4227	MMSL
d01120	MMSL
108718008	SNOMEDCT_US
386899002	SNOMEDCT_US
4020594	VANDF
004112	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0888	SUSPENSION	750 mg	ORAL	ANDA	29 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0888	SUSPENSION	750 mg	ORAL	ANDA	29 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0898	SUSPENSION	750 mg	ORAL	ANDA	29 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0898	SUSPENSION	750 mg	ORAL	ANDA	29 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1796	SUSPENSION	1500 mg	ORAL	ANDA	29 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1796	SUSPENSION	1500 mg	ORAL	ANDA	29 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0547	SUSPENSION	750 mg	ORAL	NDA	25 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0547	SUSPENSION	750 mg	ORAL	NDA	25 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0547	SUSPENSION	750 mg	ORAL	NDA	25 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0665	SUSPENSION	750 mg	ORAL	NDA	25 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0665	SUSPENSION	750 mg	ORAL	NDA	25 sections
MEPRON	HUMAN PRESCRIPTION DRUG LABEL	1	0173-0665	SUSPENSION	750 mg	ORAL	NDA	25 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0675	TABLET, FILM COATED	250 mg	ORAL	NDA	24 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0675	TABLET, FILM COATED	250 mg	ORAL	NDA	24 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0675	TABLET, FILM COATED	250 mg	ORAL	NDA	24 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0676	TABLET, FILM COATED	62.50 mg	ORAL	NDA	24 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0676	TABLET, FILM COATED	62.50 mg	ORAL	NDA	24 sections
MALARONE	HUMAN PRESCRIPTION DRUG LABEL	2	0173-0676	TABLET, FILM COATED	62.50 mg	ORAL	NDA	24 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-4160	TABLET, FILM COATED	62.50 mg	ORAL	ANDA	27 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-4160	TABLET, FILM COATED	62.50 mg	ORAL	ANDA	27 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-4162	TABLET, FILM COATED	250 mg	ORAL	ANDA	27 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	0378-4162	TABLET, FILM COATED	250 mg	ORAL	ANDA	27 sections
Atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7064	SUSPENSION	750 mg	ORAL	ANDA	24 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	10544-909	TABLET, FILM COATED	250 mg	ORAL	ANDA	26 sections
Atovaquone Oral Suspension	HUMAN PRESCRIPTION DRUG LABEL	1	10702-223	SUSPENSION	750 mg	ORAL	ANDA	21 sections
Atovaquone Oral Suspension	HUMAN PRESCRIPTION DRUG LABEL	1	10702-223	SUSPENSION	750 mg	ORAL	ANDA	21 sections
atovaquone	HUMAN PRESCRIPTION DRUG LABEL	1	16714-900	SUSPENSION	750 mg	ORAL	ANDA	25 sections
Atovaquone	Human Prescription Drug Label	1	31722-629	SUSPENSION	750 mg	ORAL	ANDA	24 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	33261-900	TABLET, FILM COATED	250 mg	ORAL	ANDA	22 sections
Atovaquone and Proguanil Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	2	42254-150	TABLET	250 mg	ORAL	ANDA	20 sections